IRAK4-IN-17

Modify Date: 2024-04-13 17:52:51

IRAK4-IN-17 structure	Common Name	IRAK4-IN-17
	CAS Number	2183503-33-3	Molecular Weight	390.39
	Density	N/A	Boiling Point	N/A
	Molecular Formula	C₁₇H₂₀F₂N₈O	Melting Point	N/A
	MSDS	N/A	Flash Point	N/A

Use of IRAK4-IN-17

IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM[1]. IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research[1].

Name	IRAK4-IN-17

Description	IRAK4-IN-17 (Compound 5) is a potent IRAK4 inhibitor with the IC50 of 1.3 nM[1]. IRAK4-IN-17 can be used in large B-cell lymphoma (DLBCL) research[1].
Related Catalog	Research Areas >> Cancer Signaling Pathways >> Immunology/Inflammation >> IRAK Signaling Pathways >> Protein Tyrosine Kinase/RTK >> IRAK
Target	IRAK4:1.3 nM (IC50)
In Vitro	IRAK4-IN-17 (0.7-40.1 μM; 72 h) selectively suppresses OCI-LY10 and TMD8 cells with MYD88 L265P mutation[1]. IRAK4-IN-17 (0.3-10 μM; 2 h) inhibits the viability of DLBCL cells by targeting IRAK4 signaling[1]. Cell Cytotoxicity Assay[1] Cell Line: OCI-LY10, TMD8, Ramos and HT cells Concentration: 0.7-40.1 μM Incubation Time: 72 hours Result: Suppressed OCI-LY10 and TMD8 cells with MYD88 L265P mutation (IC50=0.7 μM and 1.2 μM, respectively), but not Ramos and HT cell lines with WT MYD88 (IC50=11.4 μM and 40.1 μM, respectively). Western Blot Analysis[1] Cell Line: OCI-LY10 and TMD8 cells Concentration: 0.3, 1, 3 and 10 μM Incubation Time: 2 hours Result: Inhibited the phosphorylation of IRAK4 and the downstream molecules, IKKβ and NF-κB transcription factor (p65) in OCI-LY10 and TMD8 cells.
References	[1]. Yun Chen, et al. Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma. Eur J Med Chem. 2020 Mar 15;190:112092.

Molecular Formula	C₁₇H₂₀F₂N₈O
Molecular Weight	390.39